Gongwin Biopharm Holdings , Ltd. Profit Margin

Gongwin Biopharm Holdings , Ltd. (6617.TWO) currently reports a profit margin of -389.63% as of June 2026. That compares with -183.09% in the prior-year period — down 112.8% year over year. That is below the sector sector average of 13.2%. Use the charts on this page to explore Gongwin Biopharm Holdings , Ltd.'s profit margin history and peer comparisons.

Gongwin Biopharm Holdings , Ltd.'s profit margin decreased from -183.09% to -389.63% — a 112.8% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Gongwin Biopharm Holdings , Ltd.'s profit margin of -389.63% is lower than the its sector sector average of 13.2%. That is roughly 3052.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Gongwin Biopharm Holdings , Ltd.'s current -389.63% should be judged against industry norms (sector average: 13.2%) and against 6617.TWO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -389.63%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 13.2%. From there, open related valuation or income-statement pages for Gongwin Biopharm Holdings , Ltd., and consider following 6617.TWO for alerts when major investors trade the stock.